Breaking News
March 21, 2019 - Mutations in noncoding genes could play big role in regulating cancer, study finds
March 21, 2019 - A medical student’s thoughts on Match Day
March 21, 2019 - Are eggs good or bad for you?
March 21, 2019 - New analysis reveals precision oncology insights for colorectal cancer
March 21, 2019 - Pollutants appear to weaken immune system and increase pathogen virulence
March 21, 2019 - Researchers develop and validate scale for rating severity of mononucleosis
March 21, 2019 - Scientists identify generation of key immune response in mice on introducing solid food
March 21, 2019 - New nanomaterial could restore internal structure of damaged bones
March 21, 2019 - Selective destruction of prostate tumor as effective as complete prostate removal
March 21, 2019 - 2011 to 2015 Saw Increase in Psychiatric ED Visits for Youth
March 21, 2019 - Tapeworm drug targets common vulnerability in tumor cells
March 21, 2019 - Off the beaten path for global health residency
March 21, 2019 - European Parliament’s report calls on EU to develop policies to regulate endocrine-disrupting chemicals
March 21, 2019 - Women with undiagnosed diabetes in pregnancy more likely to experience stillbirths
March 21, 2019 - Fish consumption can help prevent asthma, study reveals
March 21, 2019 - Royal Holloway professors to lead new to research into curing Neurofibromatosis type 1
March 21, 2019 - NSF offers grant to improve treatment approaches for pelvic organ prolapse
March 21, 2019 - Your Apple Watch Might Help Spot a Dangerous Irregular Heartbeat
March 21, 2019 - Research team uncovers critical new clues about what goes awry in autistic brains
March 21, 2019 - From March Madness to medicine with help from mentors
March 21, 2019 - Mental health disorders among young adults may be on the increase
March 21, 2019 - New study examines smarter automatic defibrillator
March 21, 2019 - UC Riverside research shows how natural selection favors cheaters
March 21, 2019 - Mother’s diet during pregnancy can impact lung-specific genes of her offspring
March 21, 2019 - AeroForm Tissue Expanders makes breast reconstruction after mastectomy more comfortable
March 21, 2019 - New project focuses on creating more responsive, intuitive prosthetics
March 21, 2019 - New case study describes adolescent patient with rapid-onset schizophrenia and Bartonella infection
March 21, 2019 - Umass Amherst food scientist honored with 2019 Young Scientist Research Award
March 21, 2019 - Smell of skin could lead to early diagnosis for Parkinson’s
March 21, 2019 - Difference in brain connectivity may explain autism spectrum disorder
March 21, 2019 - Untangling the microbiome — with statistics
March 21, 2019 - Human microbiome metabolites enhance colon injury by enterohemorrhagic E. coli, study shows
March 21, 2019 - Written media can improve citizens’ understanding of palliative care
March 21, 2019 - New research aims to find how asthma symptoms are aggravated
March 21, 2019 - New $9.7 million NIH grant project seeks to improve hearing restoration
March 21, 2019 - Researchers measure brain metabolite levels in people with mild memory problems
March 21, 2019 - FDA approves first drug for treatment of postpartum depression in adult women
March 20, 2019 - Gene editing and designer babies experiments face global moratorium
March 20, 2019 - Major scientific study of wound care dressings wins ‘Best Clinical or Preclinical Research Award’
March 20, 2019 - Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
March 20, 2019 - Big data study identifies drugs that increase risk of psychosis in youth with ADHD
March 20, 2019 - Mystery novel and dream spur key scientific insight into heart defect | News Center
March 20, 2019 - Study measures impact of policies designed to reduce air pollution in two mega-cities
March 20, 2019 - Mild sleep apnea during pregnancy changes sugar levels and may affect infant growth patterns
March 20, 2019 - SSB and Novasep collaborate to develop new membrane chromatography systems
March 20, 2019 - Leaky valve repair improves quality of life in heart failure patients
March 20, 2019 - Diattenuation Imaging offers structural information of difficult to access brain regions
March 20, 2019 - Early sports specialization linked to increased injury rates during athletic career
March 20, 2019 - Study brings clarity about milk intake for children with Duarte galactosemia
March 20, 2019 - Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
March 20, 2019 - Maternal smoking during pregnancy increases risk of ADHD among offspring up to three-fold
March 20, 2019 - Pioneering pediatric kidney transplant surgeon Oscar Salvatierra dies at 83 | News Center
March 20, 2019 - F.D.A. Approves First Drug for Postpartum Depression
March 20, 2019 - TB remains a major public health challenge in the European region
March 20, 2019 - Most pills contain common allergens, warn experts
March 20, 2019 - Researchers discover previously unknown mechanism by which cells can sense oxygen
March 20, 2019 - World’s leading source of data on diagnosis, treatments for aortic dissection
March 20, 2019 - Breast cancer relapse predictor may soon be a reality
March 20, 2019 - Researchers identify origin of chronic pain in humans
March 20, 2019 - Two-drug combinations containing calcium channel blocker significantly lowers BP
March 20, 2019 - King’s scientists to monitor air quality exposure of 250 children
March 20, 2019 - Active substance from plant could turn into a ray of hope against eye tumors
March 20, 2019 - Preventative cardioverter defibrillator implantation is of little benefit to kidney dialysis patients
March 20, 2019 - New method based on neurofeedback may reduce anxiety
March 20, 2019 - Study explores whether alcohol consumption can have an effect on arthritis
March 20, 2019 - Merck to collaborate with GenScript for plasmid and virus manufacturing in China
March 20, 2019 - FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression
March 20, 2019 - Study examines long-term opioid use in patients with severe osteoarthritis
March 20, 2019 - Retired Stanford professor Edward Rubenstein, pioneer in intensive care medicine, dies at 94 | News Center
March 20, 2019 - Aaron Diamond AIDS Research Center to Join Columbia University
March 20, 2019 - Call for halt to human gene editing and designer babies experiments
March 20, 2019 - Study illuminates how hot spots of genetic variation evolved in the human genome
March 20, 2019 - Roundworm study suggests alternatives for treatment of schizophrenia
March 20, 2019 - Sphingotec reports new applications of bio-ADM at 39th ISICEM
March 20, 2019 - Preventing falls through free community-based screenings for older adults
March 20, 2019 - AAOS: Supplement Use Low in Patients With Osteoporosis, Hip Fracture
March 20, 2019 - Does intensive blood pressure control reduce dementia?
March 20, 2019 - Nut consumption could be key to better cognitive health in older people
March 20, 2019 - Drinking hot tea associated with increased risk of esophageal cancer
March 20, 2019 - Androgen receptor plays vital role in regulating multiple mitochondrial processes
CureMatch’s co-founder is co-author of new article in Cancer Discovery journal

CureMatch’s co-founder is co-author of new article in Cancer Discovery journal

image_pdfDownload PDFimage_print

Igor F. Tsigelny, Ph.D., Co-founder and Chief Strategic Officer at CureMatch® and research professor at University of California, San Diego, is a co-author of “Genomic landscape of cell-free DNA in patients with colorectal cancer” in Cancer Discovery along with group of colleagues from Duke University Medical Center, University of Texas MD Anderson Cancer Center, Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, Caris Life Sciences, and Guardant Health, Inc. organized by the Drs. Ryan B. Corcoran and Scott Kopetz. This study represents one of the largest-scale research projects comparing genomic profiling of cfDNA versus direct tumor sequencing.

The current Cancer Discovery article highlights how liquid biopsy techniques, which apply genomic sequencing of circulating DNA isolated from a small vial of blood, can effectively detect cellular mutations in colorectal cancer (CRC) patients. For the study, cell-free DNA (cfDNA) was collected via liquid biopsies from 1,397 CRC patients and the genomic information was compared to three independent tissue-based sequencing summaries. It was found that the liquid biopsy approach detects genomic alterations at frequencies comparable to those observed by direct tumor sequencing. Furthermore, the cfDNA also identified new mutations and offered insights into tumor therapeutic resistance.

The results of the study suggest that cfDNA profiling can effectively define the genomic landscape of cancer and yield important biologic insights. This is very significant because liquid biopsies can identify potentially important genomic alterations in patients for whom traditional biopsies may be difficult in terms of risk or cost. The blood test is relatively non-invasive and inexpensive when compared with tissue biopsy and facilitates the collection of multiple specimens over time, something that is challenging to do with tissue biopsy.

Both oncologists and their patients like the idea of a non-invasive test to monitor cancer. Cell-free DNA testing can identify mechanisms of resistance as well as future treatment options. The cfDNA test in conjunction with computational modeling can be used to adjust therapy as appropriate for those patients progressing after initial treatment. Biopsy-free testing accelerates clinical research and transforms precision medicine.

Genetic mutation discoveries lead directly to personalized medicine options. Selection of cancer drugs is the next step after genomic sequencing. This requires a clear understanding of the possible impacts of known aberrations to activity and drug resistance of the affected genes. In the Cancer Discovery article, Dr. Tsigelny theoretically elucidated functional changes of protein EGFR resistance to drugs caused by the specific mutations.

“One of the first and major steps in precision medicine is elucidation of functional impacts of gene aberrations. Such information sometimes exists in publications, but in the vast majority of cases, it does not. Thus, one needs to use computational modeling and simulations to predict possible gene activation or inhibition leading to deleterious effects and determine which mutations lead to an increased resistance to known drugs. When such work is done, the next steps are straightforward,” states Dr. Tsigelny.

Research shows that genetic markers of cancer offer some of the best indicators to recommend personalized treatments and improve survival rates. Identification of specific genetic mutations can provide oncologists with the critical information necessary to effectively recommend therapeutic strategies that overcome resistance mechanisms. As the genomic landscape of oncology is being established, researchers such as Tsigelny are offering breakthroughs for oncologists with practical technological applications.

Dr. Tsigelny is one of the major developers of the CureMatch computational system which utilizes proprietary algorithms to distill over 4.5 million combinations of commonly-used as well as newly approved cancer treatments found in massive pharmacological and clinical archives into actionable intelligence for oncologists. CureMatch is an evidence-based precision medicine system which enables oncologists to offer Personalized Combination Therapy® options to their patients.

A cancer patient’s tumor profiling data is required to use CureMatch, either tissue or cfDNA. The mutations that are specific to each individual patient’s cancer are identified, and the CureMatch computational analysis generates a PreciGENE Score which reflects the degree to which a therapy or combination of therapies matches a patient’s biomarker profile. It is represented by a percentage and may be used to compare potential treatment regimens. Determining the synergisms of oncology drugs allows potential mono-therapies, two-drug combinations, and three-drug combinations to be scored and ranked to target specific molecular aberrations.

“The growing field of genomics is driving personalized medicine for cancer care, and Igor F. Tsigelny is a biomedical researcher advancing intelligent computing systems to assist oncologists,” stated Stephane Richard Ph.D., CureMatch President and CEO.

Source:

https://www.curematch.com/press/press-releases/precision-oncology-company-curematch-cso-co-author-cancer-discovery-journal-article/

Tagged with:

About author

Related Articles